The DOI matches its Crossref record; 162 of the 165 references it cites were found in a registry or an index.
Association of metabolic syndrome and chronic kidney disease
Open accessAbstract
The prevalence of kidney disease is increasing rapidly worldwide, reflecting rising rates of obesity, diabetes, and associated metabolic syndrome (MetS). Chronic kidney disease and related comorbidities such as obesity, diabetes, and hypertension place a significant financial burden on healthcare systems. Despite the widespread use of RAAS inhibitors, intensive blood pressure and glycemic control, and newer therapeutic options consisting of sodium/glucose cotransporter-2 (SGLT-2) inhibitors or glucagon-like peptide-1 (GLP-1) receptor agonists, a significant risk of progression to end-stage renal disease remains in the high-risk obese and diabetic population. The MetS is a cluster of cardiovascular risk factors that adversely affect the development and progression of chronic kidney failure. According to the criteria of the World Health Organization, it is defined by visceral adiposity, impaired glucose tolerance or insulin resistance, atherogenic dyslipidemia, raised blood pressure, and microalbuminuria with a albumin-to-creatinine ratio ≥30 mg/g. At molecular level MetS is marked by a proinflammatory state and increased oxidative stress leading to various pathophysiological changes causing endothelial dysfunction and a hypercoagulable state. Because the kidney is a highly vascularized organ, it is especially susceptible for those microvascular changes. Therefore, the MetS and its individual components are associated with the premature development, acceleration, and progressio…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although the study was not designed to examine mechanism(s) underlying CVD risk reduction in CKM, cardioprotective properties of EPA that offset inflammation and oxidative stress while improving endothelial function may have been operative in this high-risk phenotype [[15], [16], [17], [18]].”
From Icosapent ethyl reduces CVD risk in cardiovascular-kidney-metabolic syndrome: REDUCE-IT CKM (2026) · cites this paper as [17]
Citations
Cites
Alberti, K. G. M. M., Eckel, R. H., Grundy, S. M., Zimmet, P. Z., Cleeman, J. I., Donato, K. A., Fruchart, J.-C., James, W. P. T., Loria, C. M., & Smith, S. C. (2009) · Circulation · doi:10.1161/circulationaha.109.192644 · Cited by 14,860
2018 ESC/ESH Guidelines for the management of arterial hypertension
Williams, B., Mancia, G., Spiering, W., Agabiti Rosei, E., Azizi, M., Burnier, M., Clement, D. L., Coca, A., de Simone, G., Dominiczak, A., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy339 · Cited by 10,286
The metabolic syndrome—a new worldwide definition
Alberti, K. G. M., Zimmet, P., & Shaw, J. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67402-8 · Cited by 9,352
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Dapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618
Cardiovascular and renal outcomes with empagliflozin in heart failure
Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., Januzzi, J., Verma, S., Tsutsui, H., Brueckmann, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022190 · Cited by 5,206
Eslam, M., Newsome, P. N., Sarin, S. K., Anstee, Q. M., Targher, G., Romero-Gomez, M., Zelber-Sagi, S., Wai-Sun Wong, V., Dufour, J.-F., Schattenberg, J. M., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.039 · Cited by 4,472
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838 · cited 1×
“45,150,151 Thereby, reduction in the liver, visceral, and subcutaneous fat contents have been observed.”
BackgroundBanting lecture 1988. Role of insulin resistance in human disease.
Reaven, G. (1988) · Diabetes · doi:10.2337/diabetes.37.12.1595 · Cited by 3,801
Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes
Bakris, G. L., Agarwal, R., Anker, S. D., Pitt, B., Ruilope, L. M., Rossing, P., Kolkhof, P., Nowack, C., Schloemer, P., Joseph, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2025845 · Cited by 2,935 · cited 1×
“81 In animal models, finerenone was able to oppose MetS-associated cardiac dysfunction and nephropathy.”
BackgroundEmpagliflozin in Patients with Chronic Kidney Disease
The EMPA-KIDNEY Collaborative Group (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2204233 · Cited by 2,754 · cited 1×
“…objected to the same limitations as metformin: SGLT2i should not be administered in patients with eGFR 20 ml/min/1.73 m 2 and GLP-1R agonists in those with eGFR 15 ml/min/1.73 153 The detailed presentation of the many pleiotropic actions of these drug classes are beyond the scope of this review.”
BackgroundInfluentialComment on the provisional report from the WHO consultation
(1999) · Diabetic Medicine · doi:10.1046/j.1464-5491.1999.00059.x · Cited by 1,820
Gut microbial metabolites in obesity, NAFLD and T2DM
Canfora, E. E., Meex, R. C. R., Venema, K., & Blaak, E. E. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0156-z · Cited by 1,493
Javaheri, S., Barbe, F., Campos-Rodriguez, F., Dempsey, J. A., Khayat, R., Javaheri, S., Malhotra, A., Martinez-Garcia, M. A., Mehra, R., Pack, A. I., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.11.069 · Cited by 1,434
KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
Rossing, P., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2022) · Kidney International · doi:10.1016/j.kint.2022.06.008 · Cited by 1,373
Obesity-Induced Hypertension: Interaction of Neurohumoral and Renal Mechanisms
Hall, J. E., do Carmo, J. M., da Silva, A. A., Wang, Z., & Hall, M. E. (2015) · Circulation Research · doi:10.1161/circresaha.116.305697 · Cited by 1,360
Salt-responsive gut commensal modulates TH17 axis and disease
Wilck, N., Matus, M. G., Kearney, S. M., Olesen, S. W., Forslund, K., Bartolomaeus, H., Haase, S., Mähler, A., Balogh, A., Markó, L., et al. (2017) · Nature · doi:10.1038/nature24628 · Cited by 1,310
Obesity-related glomerulopathy: An emerging epidemic
Kambham, N., Markowitz, G. S., Valeri, A. M., Lin, J., & D’Agati, V. D. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.0590041498.x · Cited by 1,288
Obesity, Weight Gain, and the Risk of Kidney Stones
Taylor, E. N. (2005) · JAMA · doi:10.1001/jama.293.4.455 · Cited by 1,193
Astrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163
Khan, S. R., Pearle, M. S., Robertson, W., Gambaro, G., Canales, B. K., Doizi, S., Traxer, O., & Tiselius, H. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.8 · Cited by 1,103
Trends in the Prevalence of Metabolic Syndrome in the United States, 2011-2016
Hirode, G., & Wong, R. J. (2020) · JAMA · doi:10.1001/jama.2020.4501 · Cited by 936
Glomerular hyperfiltration in diabetes: mechanisms, clinical significance, and treatment
Tonneijck, L., Muskiet, M. H. A., Smits, M. M., van Bommel, E. J., Heerspink, H. J. L., van Raalte, D. H., & Joles, J. A. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016060666 · Cited by 887
Alberti, K. G. M. M., Eckel, R. H., Grundy, S. M., Zimmet, P. Z., Cleeman, J. I., Donato, K. A., Fruchart, J., James, W. P. T., Loria, C. M., & Smith, S. C. (2009) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · Cited by 852
Kaplan, N. M. (1989) · Archives of Internal Medicine · doi:10.1001/archinte.1989.00390070054005 · Cited by 842
The gut microbiota and the brain–gut–kidney axis in hypertension and chronic kidney disease
Yang, T., Richards, E. M., Pepine, C. J., & Raizada, M. K. (2018) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0018-2 · Cited by 753
Once-weekly semaglutide in adolescents with obesity
Weghuber, D., Barrett, T., Barrientos-Pérez, M., Gies, I., Hesse, D., Jeppesen, O. K., Kelly, A. S., Mastrandrea, L. D., Sørrig, R., & Arslanian, S. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2208601 · Cited by 730
Obesity Pathogenesis: An Endocrine Society Scientific Statement
Schwartz, M. W., Seeley, R. J., Zeltser, L. M., Drewnowski, A., Ravussin, E., Redman, L. M., & Leibel, R. L. (2017) · Endocrine Reviews · doi:10.1210/er.2017-00111 · Cited by 727 · cited 1×
“135 However, the recurrence rate is high, 136 and many patients are unable to maintain sufficient weight loss to significantly reduce their risk for cardiometabolic and renal disease.”
BackgroundThe National Cholesterol Education Program
Cleeman, J. I. (1989) · Clinics in Laboratory Medicine · doi:10.1016/s0272-2712(18)30638-3 · Cited by 711
Obesity, kidney dysfunction and hypertension: mechanistic links
Hall, J. E., do Carmo, J. M., da Silva, A. A., Wang, Z., & Hall, M. E. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0145-4 · Cited by 654
Tuttle, K. R., Lakshmanan, M. C., Rayner, B., Busch, R. S., Zimmermann, A. G., Woodward, D. B., & Botros, F. T. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30104-9 · Cited by 648
NAFLD as a Continuum: From Obesity to Metabolic Syndrome and Diabetes
Godoy-Matos, A. F., Silva Júnior, W. S., & Valerio, C. M. (2020) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-020-00570-y · Cited by 643
Hypertension in CKD: Core Curriculum 2019
Ku, E., Lee, B. J., Wei, J., & Weir, M. R. (2019) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2018.12.044 · Cited by 582
Abate, N. I., Chandalia, M., Cabo-Chan, A. V., Moe, O. W., & Sakhaee, K. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00386.x · Cited by 564
Leoni, S., Tovoli, F., Napoli, L., Serio, I., Ferri, S., & Bolondi, L. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i30.3361 · Cited by 560
The Effects of Weight Loss on Renal Function in Patients with Severe Obesity
Chagnac, A., Weinstein, T., Herman, M., Hirsh, J., Gafter, U., & Ori, Y. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000068462.38661.89 · Cited by 537
Hypertension-Linked Pathophysiological Alterations in the Gut
Santisteban, M. M., Qi, Y., Zubcevic, J., Kim, S., Yang, T., Shenoy, V., Cole-Jeffrey, C. T., Lobaton, G. O., Stewart, D. C., Rubiano, A., et al. (2017) · Circulation Research · doi:10.1161/circresaha.116.309006 · Cited by 525
Shibata, S., Nagase, M., Yoshida, S., Kawarazaki, W., Kurihara, H., Tanaka, H., Miyoshi, J., Takai, Y., & Fujita, T. (2008) · Nature Medicine · doi:10.1038/nm.1879 · Cited by 463
NAFLD as a driver of chronic kidney disease
Byrne, C. D., & Targher, G. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.01.013 · Cited by 449
Gluttony, sloth and the metabolic syndrome: a roadmap to lipotoxicity
Unger, R. H., & Scherer, P. E. (2010) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2010.01.009 · Cited by 436
Angeli, P., García–Tsao, G., Nadim, M. K., & Parikh, C. R. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.07.002 · Cited by 435
Role of insulin resistance in human disease
Reaven, G. M. (1997) · Nutrition · doi:10.1016/s0899-9007(96)00380-2 · Cited by 397
Shimizu, M., Suzuki, K., Kato, K., Jojima, T., Iijima, T., Murohisa, T., Iijima, M., Takekawa, H., Usui, I., Hiraishi, H., et al. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13520 · Cited by 393
Huby, A.-C., Antonova, G., Groenendyk, J., Gomez-Sanchez, C. E., Bollag, W. B., Filosa, J. A., & de Chantemèle, E. J. B. (2015) · Circulation · doi:10.1161/circulationaha.115.018226 · Cited by 376
Garofalo, C., Borrelli, S., Minutolo, R., Chiodini, P., De Nicola, L., & Conte, G. (2017) · Kidney International · doi:10.1016/j.kint.2016.12.013 · Cited by 363
Circulating Ceramides Predict Cardiovascular Outcomes in the Population-Based FINRISK 2002 Cohort
Havulinna, A. S., Sysi‐Aho, M., Hilvo, M., Kauhanen, D., Hurme, R., Ekroos, K., Salomaa, V. V., & Laaksonen, R. (2016) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.116.307497 · Cited by 345
Stojsavljević, S. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i48.18070 · Cited by 336
The Nephrotic Syndrome: A Complication of Massive Obesity
Weisinger, J. R., Kempson, R. L., Eldridge, F. L., & Swenson, R. S. (1974) · Annals of Internal Medicine · doi:10.7326/0003-4819-81-4-440 · Cited by 318
Boon, J., Hoy, A. J., Stark, R., Brown, R. D., Meex, R. C. R., Henstridge, D. C., Schenk, S., Meikle, P. J., Horowitz, J. F., Kingwell, B. A., et al. (2012) · Diabetes · doi:10.2337/db12-0686 · Cited by 317
The Modern Spectrum of Renal Biopsy Findings in Patients with Diabetes
Sharma, S. G., Bomback, A. S., Radhakrishnan, J., Herlitz, L., Stokes, M. B., Markowitz, G. S., & D’Agati, V. D. (2013) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02510213 · Cited by 313
Predictors of bleeding complications in percutaneous ultrasound-guided renal biopsy
Manno, C., Strippoli, G. F., Arnesano, L., Bonifati, C., Campobasso, N., Gesualdo, L., & Schena, F. P. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00922.x · Cited by 308
Sterol regulatory element binding protein 1 couples mechanical cues and lipid metabolism
Bertolio, R., Napoletano, F., Mano, M., Maurer‐Stroh, S., Fantuz, M., Zannini, A., Bicciato, S., Sorrentino, G., & Sal, G. D. (2019) · Nature Communications · doi:10.1038/s41467-019-09152-7 · Cited by 304
Noubiap, J. J., Nansseu, J. R., Lontchi-Yimagou, E., Nkeck, J. R., Nyaga, U. F., Ngouo, A. T., Tounouga, D. N., Tianyi, F. L., Foka, A. J., Ndoadoumgue, A. L., et al. (2022) · The Lancet Child & Adolescent Health · doi:10.1016/s2352-4642(21)00374-6 · Cited by 304
Metabolic syndrome and chronic kidney disease
Singh, A. K., & Kari, J. A. (2013) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0b013e32835dda78 · Cited by 299
Semaglutide 2.4 mg for the treatment of obesity: key elements of the STEP trials 1 to 5
Kushner, R. F., Calanna, S., Davies, M., Dicker, D., Garvey, W. T., Goldman, B., Lingvay, I., Thomsen, M., Wadden, T. A., Wharton, S., et al. (2020) · Obesity · doi:10.1002/oby.22794 · Cited by 288
Kidney Stones 2012: Pathogenesis, Diagnosis, and Management
Sakhaee, K., Maalouf, N. M., & Sinnott, B. P. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3492 · Cited by 284
Metabolic Syndrome and Risk of Acute Myocardial Infarction
Mente, A., Yusuf, S., Islam, S., McQueen, M., Tanomsup, S., Onen, C. L., Rangarajan, S., Gerstein, H. C., & Anand, S. S. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.12.053 · Cited by 261
Noubiap, J. J., Nansseu, J. R., Lontchi‐Yimagou, E., Nkeck, J. R., Nyaga, U. F., Ngouo, A. T., Tounouga, D. N., Tianyi, F., Foka, A. J., Ndoadoumgue, A. L., et al. (2022) · LSTM Online Archive (Liverpool School of Tropical Medicine) · Cited by 254
Systematic Review and Meta-Analysis of Native Kidney Biopsy Complications
Poggio, E. D., McClelland, R. L., Blank, K. N., Hansen, S. L., Bansal, S., Bomback, A. S., Canetta, P. A., Khairallah, P., Kiryluk, K., Lecker, S. H., et al. (2020) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04710420 · Cited by 252
Talbott, J. H., & TERPLAN, K. L. (1960) · Medicine · doi:10.1097/00005792-196012000-00001 · Cited by 252
Targher, G., Bertolini, L., Rodella, S., Lippi, G., Zoppini, G., & Chonchol, M. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.05050610 · Cited by 237
Zimmet, P., Boyko, E. J., Collier, G. R., & de Courten, M. (1999) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1999.tb07783.x · Cited by 234
Protection of the kidney by thiazolidinediones: An assessment from bench to bedside
Sarafidis, P. A., & Bakris, G. L. (2006) · Kidney International · doi:10.1038/sj.ki.5001620 · Cited by 221
Obesity and Cardiac Remodeling in Adults: Mechanisms and Clinical Implications
Alpert, M. A., Karthikeyan, K., Abdullah, O., & Ghadban, R. (2018) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2018.07.012 · Cited by 221
Progressive Renal Decline: The New Paradigm of Diabetic Nephropathy in Type 1 Diabetes
Królewski, A. S. (2015) · Diabetes Care · doi:10.2337/dc15-0184 · Cited by 220
Management of cardiovascular diseases in patients with obesity
Lavie, C. J., Arena, R., Alpert, M. A., Milani, R. V., & Ventura, H. O. (2018) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.108 · Cited by 218
Chronic Kidney Disease in Kidney Stone Formers
Rule, A. D., Krambeck, A. E., & Lieske, J. C. (2011) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.10651110 · Cited by 217
Cortinovis, M., Perico, N., Ruggenenti, P., Remuzzi, A., & Remuzzi, G. (2022) · Nature Reviews Nephrology · doi:10.1038/s41581-022-00559-y · Cited by 214
Reisinger, C., Nkeh-Chungag, B. N., Fredriksen, P. M., & Goswami, N. (2020) · International Journal of Obesity · doi:10.1038/s41366-020-00713-1 · Cited by 213
Sleep Apnea and Cardiovascular Disease: An Enigmatic Risk Factor
Floras, J. S. (2018) · Circulation Research · doi:10.1161/circresaha.118.310783 · Cited by 209
Oxalate Nephropathy Complicating Roux-en-Y Gastric Bypass
Nasr, S. H., D’Agati, V. D., Said, S. M., Stokes, M. B., Largoza, M. V., Radhakrishnan, J., & Markowitz, G. S. (2008) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02940608 · Cited by 201
Uric acid and inflammation in kidney disease
Jung, S. W., Kim, S.-M., Kim, Y., Lee, S. H., & Moon, J.-Y. (2020) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00272.2019 · Cited by 201
Immunologic and endocrine functions of adipose tissue: implications for kidney disease
Zhu, Q., & Scherer, P. E. (2018) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.157 · Cited by 200
Bray, J. J. H., Foster‐Davies, H., Salem, A., Hoole, A. L., Obaid, D. R., Halcox, J. P. J., & Stephens, J. W. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14399 · Cited by 194
Jones, D. W., Kim, J. S., Andrew, M. E., Kim, S. J., & Hong, Y. P. (1994) · Journal of Hypertension · doi:10.1097/00004872-199412000-00018 · Cited by 191
The metabolic syndrome and chronic kidney disease
Zhang, X., & Lerman, L. O. (2016) · Translational research · doi:10.1016/j.trsl.2016.12.004 · Cited by 185
Barrera-Chimal, J., Estrela, G. R., Lechner, S. M., Giraud, S., El Moghrabi, S., Kaaki, S., Kolkhof, P., Hauet, T., & Jaisser, F. (2018) · Kidney International · doi:10.1016/j.kint.2017.12.016 · Cited by 183
The Renin Angiotensin Aldosterone System in Obesity and Hypertension
Cabandugama, P. K., Gardner, M. J., & Sowers, J. R. (2017) · Medical Clinics of North America · doi:10.1016/j.mcna.2016.08.009 · Cited by 168
Metabolic syndrome and chronic kidney disease: Current status and future directions
Prasad, G. V. R. (2014) · World Journal of Nephrology · doi:10.5527/wjn.v3.i4.210 · Cited by 164
Metformin improves endothelial function in patients with metabolic syndrome
VITALE, C., MERCURO, G., CORNOLDI, A., FINI, M., VOLTERRANI, M., & ROSANO, G. M. C. (2005) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2005.01531.x · Cited by 164
The Association of Increasing Body Mass Index and Kidney Stone Disease
Semins, M. J., Shore, A. D., Makary, M. A., Magnuson, T. H., Johns, R. A., & Matlaga, B. R. (2009) · The Journal of Urology · doi:10.1016/j.juro.2009.09.085 · Cited by 160
Renal Dysfunction, Rather Than Nonrenal Vascular Dysfunction, Mediates Salt-Induced Hypertension
Hall, J. E. (2016) · Circulation · doi:10.1161/circulationaha.115.018526 · Cited by 152
Lopes, H. F., Corrêa‐Giannella, M. L., Consolim‐Colombo, F. M., & Egan, B. M. (2016) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-016-0156-2 · Cited by 147
Sellmayr, M., Petzsche, M. R. H., Ma, Q., Krüger, N., Liapis, H., Brink, A., Lenz, B. F., Angelotti, M. L., Gnemmi, V., Kuppe, C., et al. (2020) · Journal of the American Society of Nephrology · doi:10.1681/asn.2020040523 · Cited by 147
Long-term Morbidity Following Jejunoileal Bypass
Requarth, J. A. (1995) · Archives of Surgery · doi:10.1001/archsurg.1995.01430030088018 · Cited by 145
Metabolic syndrome-related kidney injury: a review and update
Lin, L., Tan, W., Pan, X., Tian, E., Wu, Z., & Yang, J. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.904001 · Cited by 139
Xia, M., Bian, H., & Gao, X. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00877 · Cited by 139
Whaley‐Connell, A. T., & Sowers, J. R. (2017) · Kidney International · doi:10.1016/j.kint.2016.12.034 · Cited by 138
Pathophysiology and Management of Hyperoxaluria and Oxalate Nephropathy: A Review
Demoulin, N., Aydın, S., Gillion, V., Morelle, J., & Jadoul, M. Y. (2021) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2021.07.018 · Cited by 136
Characteristics of healthy vascular ageing in pooled population-based cohort studies
Nilsson, P. M., Laurent, S., Cunha, P., Olsen, M. H., Rietzschel, E. R., Franco, O. H., Ryliškytė, L., Strazhesko, I. D., Vlachopoulos, C. V., Chen, C., et al. (2018) · Journal of Hypertension · doi:10.1097/hjh.0000000000001824 · Cited by 132
Reappraising the spectrum of AKI and hepatorenal syndrome in patients with cirrhosis
Velez, J. C. Q., Therapondos, G., & Juncos, L. A. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0218-4 · Cited by 131
Mineralocorticoid Receptor Activation Promotes Vascular Cell Calcification
Jaffe, I. Z., Tintut, Y., Newfell, B. G., Demer, L. L., & Mendelsohn, M. E. (2007) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000258414.59393.89 · Cited by 130
Diabetic eNOS knockout mice develop distinct macro- and microvascular complications
Mohan, S., Reddick, R. L., Musi, N., Horn, D. A., Yan, B., Prihoda, T. J., Natarajan, M., & Abboud‐Werner, S. L. (2008) · Laboratory Investigation · doi:10.1038/labinvest.2008.23 · Cited by 127
Metabolic syndrome and stroke: A meta-analysis of prospective cohort studies
Li, X., Li, X., Lin, H., Fu, X., Lin, W., Li, M., Zeng, X., & Gao, Q. (2017) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2017.01.018 · Cited by 125
Straznicky, N. E., Grima, M. T., Lambert, É., Eikelis, N., Dawood, T., Lambert, G. W., Nestel, P. J., Masuo, K., Sari, C. I., Chopra, R., et al. (2010) · Journal of Hypertension · doi:10.1097/hjh.0b013e3283418875 · Cited by 123
Acute kidney injury in acute-on-chronic liver failure: where does hepatorenal syndrome fit?
Davenport, A., Sheikh, M., Lamb, E. J., Agarwal, B., & Jalan, R. (2017) · Kidney International · doi:10.1016/j.kint.2017.04.048 · Cited by 115
Urbanet, R., Nguyen Dinh Cat, A., Feraco, A., Venteclef, N., El Mogrhabi, S., Sierra-Ramos, C., Alvarez de la Rosa, D., Adler, G. K., Quilliot, D., Rossignol, P., et al. (2015) · Hypertension · doi:10.1161/hypertensionaha.114.04981 · Cited by 114
Chemoreflexes, Sleep Apnea, and Sympathetic Dysregulation
Mansukhani, M. P., Kara, T., Caples, S. M., & Somers, V. K. (2014) · Current Hypertension Reports · doi:10.1007/s11906-014-0476-2 · Cited by 112
Phrueksotsai, S., Pinyopornpanish, K., Euathrongchit, J., Leerapun, A., Phrommintikul, A., Buranapin, S., Chattipakorn, N., & Thongsawat, S. (2021) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15580 · Cited by 104
Accuracy of GFR estimation in obese patients.
Lemoine, S., Guebre-Egziabher, F., Sens, F., Nguyen-Tu, M.-S., Juillard, L., Dubourg, L., & Hadj-Aissa, A. (2014) · American Society of Nephrology. Clinical Journal · doi:10.2215/cjn.03610413 · Cited by 103
Adipocytes, aldosterone and obesity-related hypertension
Cat, A. N. D., Friederich‐Persson, M., White, A. D., & Touyz, R. M. (2016) · Journal of Molecular Endocrinology · doi:10.1530/jme-16-0025 · Cited by 94
Butler, M. J., Ramnath, R. D., Kadoya, H., Desposito, D., Riquier‐Brison, A., Ferguson, J., Onions, K. L., Ogier, A. S., Elhegni, H. E., Coward, R. J., et al. (2018) · Kidney International · doi:10.1016/j.kint.2018.08.024 · Cited by 94
Obesity and chronic kidney disease
Nehus, E. J. (2018) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000000586 · Cited by 89
Jinjuvadia, R., Antaki, F., Lohia, P., & Liangpunsakul, S. (2016) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000000666 · Cited by 82
Early histological changes in the kidney of people with morbid obesity
Goumenos, D. S., Kawar, B., Nahas, M. E., Conti, S., Wagner, B. E., Spyropoulos, C., Vlachojannis, J. G., Benigni, A., & Kalfarentzos, F. (2009) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfp329 · Cited by 82
Renal Biopsy in Type 2 Diabetic Patients
Espinel, E., Agraz, I., Ibernón, M., Ramos-Terrades, N., Fort, J., & Serón, D. (2015) · Journal of Clinical Medicine · doi:10.3390/jcm4050998 · Cited by 81
Bloomgarden, Z. T. (2003) · Diabetes Care · doi:10.2337/diacare.26.4.1297 · Cited by 81
Lee, T. H., Chen, J., Wu, C., Yang, C., & Yang, H. (2021) · Diagnostics · doi:10.3390/diagnostics11091674 · Cited by 81
Kouvari, M., Chrysohoou, C., Skoumas, J., Pitsavos, C., Panagiotakos, D. B., & Mantzoros, C. S. (2022) · Metabolism · doi:10.1016/j.metabol.2021.154893 · Cited by 74
Physiological role of adiponectin in different tissues: a review
Esmaili, S., Hemmati, M., & Karamian, M. (2018) · Archives of Physiology and Biochemistry · doi:10.1080/13813455.2018.1493606 · Cited by 73
The Role of Advanced Glycation End Products and Its Soluble Receptor in Kidney Diseases
Steenbeke, M., Speeckaert, R., Desmedt, S., Glorieux, G., Delanghe, J., & Speeckaert, M. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073439 · Cited by 73
Adeosun, S. O., Gordon, D. M., Weeks, M. F., Moore, K. H., Hall, J. E., Hinds, T. D., & Stec, D. E. (2018) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00495.2017 · Cited by 73
Rosenstock, J. L., Joab, T. M. J., DeVita, M. V., Yang, Y., Sharma, P., & Bijol, V. (2021) · Clinical Kidney Journal · doi:10.1093/ckj/sfab145 · Cited by 71
Distribution of renal medullary hyaluronan in lean and obese rabbits
Dwyer, T. M., Banks, S. A., Alonso-Galicia, M., Cockrell, K., Carroll, J. F., Bigler, S. A., & Hall, J. E. (2000) · Kidney International · doi:10.1046/j.1523-1755.2000.00218.x · Cited by 68
Systematic review and meta-analysis: SGLT2 inhibitors, blood pressure and cardiovascular outcomes
Benham, J. L., Booth, J. E., Sigal, R. J., Daskalopoulou, S. S., Leung, A. A. C., & Rabi, D. M. (2021) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2021.100725 · Cited by 64
Bray, J. J. H., Foster-Davies, H., & Stephens, J. W. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108368 · Cited by 64
Georgianos, P. I., & Agarwal, R. (2022) · American Journal of Hypertension · doi:10.1093/ajh/hpac124 · Cited by 63
van Ruiten, C. C., Smits, M. M., Kok, M. D., Serné, E. H., van Raalte, D. H., Kramer, M. H. H., Nieuwdorp, M., & IJzerman, R. G. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01492-x · Cited by 57
Lachaux, M., Barrera‐Chimal, J., Nicol, L., Rémy‐Jouet, I., Renet, S., Dumesnil, A., Wecker, D., Richard, V. J., Kolkhof, P., Jaisser, F., et al. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13393 · Cited by 54
Risk of chronic kidney disease in patients with kidney stones—a nationwide cohort study
Chuang, T.-F., Hung, H., Li, S., Lee, M.-W., Pai, J., & Hung, C. (2020) · BMC Nephrology · doi:10.1186/s12882-020-01950-2 · Cited by 54
The spectrum of kidney biopsy findings in patients with morbid obesity
Choung, H. Y. G., Bomback, A. S., Stokes, M. B., Santoriello, D., Campenot, E. S., Batal, I., Markowitz, G. S., & D’Agati, V. D. (2019) · Kidney International · doi:10.1016/j.kint.2018.11.026 · Cited by 51
Adherence to a Healthy Lifestyle and All-Cause Mortality in CKD
Ricardo, A. C., Madero, M., Yang, W. P., Anderson, C. A. M., Menezes, M., Fischer, M. J., Turyk, M. E., Daviglus, M. L., & Lash, J. P. (2013) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00600112 · Cited by 49
The Impact of Overnutrition on Insulin Metabolic Signaling in the Heart and the Kidney
Pulakat, L., DeMarco, V. G., Whaley‐Connell, A. T., & Sowers, J. R. (2011) · Cardiorenal Medicine · doi:10.1159/000327140 · Cited by 48
The role of metabolic syndrome in sudden cardiac death risk: Recent evidence and future directions
Tirandi, A., Carbone, F., Montecucco, F., & Liberale, L. (2021) · European Journal of Clinical Investigation · doi:10.1111/eci.13693 · Cited by 48
Mantovani, A., Lunardi, G., Bonapace, S., Dugo, C., Altomari, A., Molon, G., Conti, A., Bovo, C., Laaksonen, R., Byrne, C. D., et al. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2020.03.003 · Cited by 47
Yoshida, S., Ishizawa, K., Ayuzawa, N., Ueda, K., Takeuchi, M., Kawarazaki, W., Fujita, T., & Nagase, M. (2014) · Nephron Experimental Nephrology · doi:10.1159/000358758 · Cited by 45
Lerma, E. V., & Wilson, D. J. (2022) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2022.2094770 · Cited by 42
Endothelial Insulin and IGF-1 Receptors: When Yes Means NO
Muniyappa, R., & Sowers, J. R. (2012) · Diabetes · doi:10.2337/db12-0654 · Cited by 39
Metabolic syndrome and nephrolithiasis.
Ramaswamy, K. A., & Shah, O. D. (2014) · PubMed Central · doi:10.3978/j.issn.2223-4683.2014.06.03 · Cited by 38
Treatment of dyslipidemia in chronic kidney disease: Effectiveness and safety of statins
Scarpioni, R. (2012) · World Journal of Nephrology · doi:10.5527/wjn.v1.i6.184 · Cited by 37
Effects of reactive oxygen species on renal tubular transport
Gonzalez‐Vicente, A., Hong, N. J., & Garvin, J. L. (2019) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00604.2018 · Cited by 35
Li, L., Yang, J., Li, F., Zhu, L., & Hao, J. (2021) · Molecular Medicine Reports · doi:10.3892/mmr.2021.11872 · Cited by 34
Metabolic Syndrome, and Not Obesity, Is Associated with Chronic Kidney Disease
Ciardullo, S., Ballabeni, C., Trevisan, R., & Perseghin, G. (2021) · American Journal of Nephrology · doi:10.1159/000518111 · Cited by 34
Increased Hyaluronic Acid in the Inner Renal Medulla of Obese Dogs
Alonso-Galicia, M., Dwyer, T. M., Herrera, G. A., & Hall, J. E. (1995) · Hypertension · doi:10.1161/01.hyp.25.4.888 · Cited by 32
Stewart, L. K., & Kline, J. A. (2020) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201907-518oc · Cited by 28
Diabetic nephropathy: a global and growing threat.
Tang, S. C. W. (2010) · PubMed · Cited by 26
Owusu, J., & Barrett, E. J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147574 · Cited by 25
Lemoine, S., Panaye, M., Pelletier, C. C., Bon, C., Juillard, L., Dubourg, L. D., & Guebre‐Egziabher, F. (2016) · American Journal of Nephrology · doi:10.1159/000447365 · Cited by 25
LaGuardia, H., Hamm, L. L., & Chen, J. (2012) · Journal of Nutrition and Metabolism · doi:10.1155/2012/652608 · Cited by 24
Chang, A. R., Batch, B. C., McGuire, H. L., Vollmer, W. M., Svetkey, L. P., Tyson, C. C., Sanguankeo, A., Anderson, C. A. M., Houston, J., & Appel, L. J. (2013) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2013.04.022 · Cited by 24
Marková, I., Miklánková, D., Hüttl, M., Kačer, P., Skibová, J., Kucera, J., Sedláček, R., Kačerová, T., Kazdová, L., & Malínská, H. (2019) · Journal of Diabetes Research · doi:10.1155/2019/8712979 · Cited by 24
Kidney disease in patients with obesity: It is not always obesity-related glomerulopathy alone
Salvatore, S., Chevalier, J. M., Kuo, S., Audia, P. F., & Seshan, S. V. (2017) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2017.04.003 · Cited by 24
Yarnoff, B., Hoerger, T. J., Shrestha, S. S., Simpson, S. K., Burrows, N. R., Anderson, A. H., Xie, D., Chen, H., Pavkov, M. E., & the CRIC Study Investigators (2018) · PLoS ONE · doi:10.1371/journal.pone.0205530 · Cited by 23
GLP-1 receptor agonists in diabetic kidney disease
Michos, E. D., & Tuttle, K. R. (2021) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.18771220 · Cited by 23
Min, S. H., Kim, S., Jeong, I., Cho, H., Jeong, J., Lee, J., Kang, H., Kim, H.-S., Park, K. S., & Lim, S. K. (2017) · Korean Circulation Journal · doi:10.4070/kcj.2017.0200 · Cited by 22
Ramírez-Jiménez, M., Morales‐Palomo, F., Moreno‐Cabañas, A., Álvarez-Jiménez, L., ORTEGA, J. F., & Mora‐Rodríguez, R. (2021) · Scandinavian Journal of Medicine and Science in Sports · doi:10.1111/sms.13949 · Cited by 22
Oxalate nephropathy in systemic sclerosis: Case series and review of the literature
Ligon, C., Hummers, L. K., & McMahan, Z. H. (2015) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2015.06.017 · Cited by 20
Fu, C.-P., Sheu, W., Lee, I., Lee, W.-J., Wang, J.-S., Liang, K.-W., Lee, W.-L., & Lin, S.-Y. (2015) · Clinical Chemistry and Laboratory Medicine · doi:10.1515/cclm-2014-0468 · Cited by 18
Eid, B. G., Neamatallah, T., Hanafy, A., El‐Bassossy, H. M., Binmahfouz, L. S., Aldawsari, H. M., Hasan, A., El-Aziz, G. S. A., Vemuri, K. V., & Makriyannis, A. (2021) · Molecules · doi:10.3390/molecules26040866 · Cited by 14
Koh, E. S., Han, K., Kim, M. K., Kim, E. S., Lee, M.-K., Nam, G. E., Hong, O., & Kwon, H. (2021) · Scientific Reports · doi:10.1038/s41598-021-81396-0 · Cited by 12
Nilsson, P. M., Laurent, S., Cunha, P. M. G. M., Olsen, M. H., Rietzschel, E., Franco, O. H., Ryliškytė, L., Strazhesko, I., Vlachopoulos, C., Chen, C.-H., et al. (2018) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · Cited by 11
Scurt, F. G., Kuczera, T., Mertens, P. R., & Chatzikyrkou, C. (2019) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-0768-5899 · Cited by 9
Self-citationCorreia‐Costa, L., Morato, M., Sousa, T., Cosme, D., Guimarães, J. T., Guerra, A., Schaefer, F. S., Afonso, A. C., Azevedo, A., & Albino‐Teixeira, A. (2015) · Pediatric Nephrology · doi:10.1007/s00467-015-3232-1 · Cited by 8
Early histological changes in the kidney of people with morbid obesity
Goumenos, D. S., Kawar, B., Nahas, M. E., Conti, S., Wagner, B., Spyropolous, C., Vlachojannis, J. G., Benigni, A., & Kalfarentzos, F. E. (2010) · Obesity and metabolism · doi:10.14341/2071-8713-5290 · Cited by 8
Stewart, L. K., Beam, D. M., Casciani, T., Cameron, S. J., & Kline, J. A. (2019) · International Journal of Cardiology · doi:10.1016/j.ijcard.2019.12.043 · Cited by 7
Scurt, F. G., Bose, K., Canbay, A. E., Mertens, P. R., & Chatzikyrkou, C. (2021) · Zeitschrift für Gastroenterologie · doi:10.1055/a-1402-1502 · Cited by 4
Self-citationMiller, W. L. (2022) · Circulation Heart Failure · doi:10.1161/circheartfailure.121.009344 · Cited by 2
Kann Allopurinol die Progression der chronischen Niereninsuffizienz verlangsamen?
Chatzikyrkou, C. (2020) · Der Nephrologe · doi:10.1007/s11560-020-00464-0 · Cited by 1
Self-citation
Research works printed but not linked: 4
- World Health O, 1999, Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO consultation. Part 1, Diagnosis and classification of diabetes mellitus
- Aihara K, 2010, Transforming growth factor‐β1 as a common target molecule for development of cardiovascular diseases, renal insufficiency and metabolic syndrome, Cardiol Res Pract, 2011
- Scurt FG, 2020, Paradigm shift in understanding acute kidney injury in patients with chronic liver disease: from pathophysiology to defining disease entities, Z Gastroenterol, 58, 254
- McMurray JJV, 2020, Dapagliflozin in patients with heart failure and reduced ejection fraction, Reply N Engl J Med, 382, 973
Cited by
Sorted by citations
Cardiovascular-kidney-metabolic syndrome – An integrative review
Kittelson, K. S., Gasparotto, A., Fillmore, N., & Gomes, R. D. S. (2024) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2024.10.012 · Cited by 102
Metabolic syndrome: epidemiology, mechanisms, and current therapeutic approaches
Hamooya, B. M., Siame, L., Muchaili, L., Masenga, S. K., & Kirabo, A. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1661603 · Cited by 117
Cao, Y., Wang, W., Xie, S., Xu, Y., & Lin, Z. (2025) · BMC Public Health · doi:10.1186/s12889-024-21131-2 · Cited by 81
Yu, W., Sun, S., Yan, Y., Zhou, H., Liu, Z., & Fu, Q. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1519925 · Cited by 70
Giangregorio, F., Mosconi, E., Debellis, M. G., Provini, S., Esposito, C., Garolfi, M., Oraka, S., KALOUDI, O., Mustafazade, G., Marín‐Baselga, R., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13195880 · Cited by 67
Metadata
- Authors
- Scurt, F. G., Ganz, M. J., Herzog, C., Bose, K., Mertens, P. R., & Chatzikyrkou, C.
- Affiliations
- University Clinic for Nephrology and Hypertension, Diabetology and Endocrinology (DE)
- Klinikum Magdeburg (DE)
- Medizinische Hochschule Hannover (DE)
- Corresponding author
- Scurt, Florian G.
- Venue
- Obesity Reviews
- Publisher
- Wiley
- Published
- 2023-10-02
- Volume
- 25
- Issue
- 1
- Pages
- e13649-e13649
- ISSN
- 1467-7881 (ISSN-L)
- 1467-789X
- OpenAlex
- W4387246542
- Cited by
- 155
- References
- 165
- Citations by year
- 2026: 50 · 2025: 75 · 2024: 29 · 2023: 1
- FWCI
- 6.77
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Obesity Reviews (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- metabolic syndrome, chronic kidney disease, obesity, diabetes mellitus, insulin resistance, microalbuminuria, endothelial dysfunction, oxidative stress, inflammation, end-stage renal disease, renal hemodynamics, renal metabolism, SGLT2 inhibitors, GLP-1 receptor agonists, renin-angiotensin system inhibitors
- MeSH terms
- Diabetes Mellitus, Humans, Insulin Resistance, Obesity, Metabolic Syndrome, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
